Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

4/14/25 8:17:08 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LENZ

Date	Price Target	Rating	Analyst
4/14/2025	$38.00 → $51.00	Overweight	Piper Sandler
3/18/2025	$60.00	Buy	TD Cowen
9/27/2024	$37.00	Outperform	Raymond James
8/12/2024	$38.00	Buy	H.C. Wainwright
4/15/2024		Outperform	William Blair
4/15/2024	$32.00	Outperform	Leerink Partners
4/10/2024	$34.00	Buy	Citigroup
3/27/2024	$28.00	Overweight	Piper Sandler